Although the specific mechanism of minocycline in RP is not fully understood, it was found able to block TLR2 and 4 and consequently inhibit the downstream nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and mitogen-activated protein kinase (MAPK) pathways (Pierdomenico et al., 2018). This evidence concerns the gene TLR2 and retinitis pigmentosa 1.